Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. 1981

R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber

The ability of insulin to inhibit its own secretion was examined in 15 normal subjects given an intravenous infusion of insulin in a dose of 0.25, 0.50, 1.0, 5.0 or 10.0 mU/kg/min for two hours. Arterial plasma insulin concentration achieved during the infusion segregated into three levels of hyperinsulinaemia: 35 +/- 1 (mean +/- SEM), 87 +/- 15 and 828 +/- 210 muU/ml. Plasma glucose concentration was kept constant at the basal level by a variable glucose infusion. Fasting C-peptide (0.29 +/- 0.02 pmol/ml) fell significantly in all subjects during hyperinsulinaemia and reached a concentration of 0.19 +/- 0.03 pmol/ml at 60 min and 0.14 +/- 0.03 at 120 min after the start of the insulin infusion. The C-peptide response was not related to the infusion dose nor to the steady state plasma insulin concentration. It is concluded that (a) basal insulin secretion as evaluated from C-peptide measurements is inhibited by small (24 +/- 3 muU/ml) physiological elevations in plasma insulin concentration independent of changes in plasma glucose, and (b) supraphysiological or even pharmacological elevations in plasma insulin do not result in a further decrease in endogenous insulin secretion above that achieved with mild hyperinsulinaemia.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
May 1982, The New England journal of medicine,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
October 1994, Diabetologia,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
March 1986, Endocrinology,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
October 1986, The Journal of clinical endocrinology and metabolism,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
November 1991, Clinical science (London, England : 1979),
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
February 1995, Endocrine journal,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
February 1992, The Journal of clinical investigation,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
December 1992, Diabetes,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
January 1973, Scandinavian journal of gastroenterology. Supplement,
R A DeFronzo, and C Binder, and J Wahren, and P Felig, and E Ferrannini, and O K Faber
December 1973, Lancet (London, England),
Copied contents to your clipboard!